Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04564027 · ClinicalTrials.gov registry record · Phase 2
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04564027 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 54 participants.
The verdict
NCT04564027, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
Interventions
- DRUG Ceralasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04564027
The ClinicalTrials.gov registry entry for NCT04564027 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ceralasertib is the first listed.
NCT04564027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04564027 about?
NCT04564027 is a clinical study titled "A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer". The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
What is the current status of trial NCT04564027?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-12-01. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT04564027?
The interventions under investigation include: Ceralasertib (DRUG).
Who is sponsoring clinical trial NCT04564027?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.